Dose Selection(Step 1), Non-inferiority(Step 2), Phase II/III Clinical Trials to Evaluate the Efficacy and Safety of Hepatitis B Virus-associated Liver Transplant Patients by Intravenously Injecting GC1102
Phase of Trial: Phase II/III
Latest Information Update: 16 May 2018
At a glance
- Drugs GC 1102 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors GC Pharma
- 25 Apr 2018 Status changed from planning to recruiting.
- 19 Jan 2018 New trial record
- 17 Jan 2018 According to a Green Cross Pharma media release, the company expects to initiate patient enrollment in early 2018 and expects to complete the trial in 5 years.